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Abstract
Background: So-Cheong-Ryong-Tang (CY), a traditional herbal formula, mainly has been shown to possess allergic
rhinitis and asthma for hundreds of years in Asian countries. Although this medicine has been attracted Asian
scientists with investigating mechanisms of action against inflammatory-related diseases, there is a little available
information on the anti-cancer effect of CY, especially on the fermented form (FCY). In this study, we explored the
chemopreventive/chemotherapeutic efficacy of FCY against cancer cells and proved the efficacy of FCY through
performing in vivo xenograft assay.
Methods: CY was fermented with bacteria and lyophilized. For analysis of the constituents of CY and FCY, high
performance liquid chromatography (HPLC)-DAD system was performed. To detect the anti-cancer effect of FCY,
cell viability assay, caspase activity assay, cell cycle analysis, and Western blot analysis were performed in AGS
human gastric cancer cells. The inhibitory effects of tumor growth by CY and FCY were evaluated in athymic nude
mice inoculated with HCT116 human colon cancer cells.
Results: As a result of analyzing the 11components present in CY and FCY, the contents of ephedrine HCl, glycyrrhizin,
gingerol, schisandrin, and gomisin A were respectively increased by fermentation in FCY. The treatment of CY or FCY
inhibited the viability of AGS cells, interestingly, the inhibition of cancer cell growth was enhanced by fermentation of
CY. FCY induced the apoptosis through activating the caspase-3, −8, and −9. Additionally, FCY regulated the activation
of mitogen-activated protein kinases (MAPKs) including extracellular signal-regulated kinase (ERK), p38, and c-Jun
NH2-terminal kinase (JNK). In vivo xenografts, administration of FCY significantly inhibited the tumor formation,
and improved the anti-tumor effect compared to that of CY in athymic nude mice.
Conclusions: FCY indicated significant anti-cancer effects, and its efficacy against tumor formation was improved
than that of CY, therefore, FCY might be used for applications of traditional medicine against cancer in modern
complementary and alternative therapeutics.
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Background
Cancer, particularly in its advanced stages, is a multifac-
torial disease that demands treatments that target mul-
tiple cellular pathways; several options are available for
this purpose. However, chemotherapy with cytotoxic
anti-cancer drugs is associated with significant side ef-
fects and offers few survival benefits for patients with
advanced malignancies. Thus, some patients and clini-
cians consider the use of alternative medicines as an-
other treatment option [1, 2].
Formulated herbal cocktails target multiple cellular
pathways to correct the dysregulated cellular functions
that are associated with the various stages of cancer de-
velopment [3]. However, herbal remedies have yet to be
fully integrated into mainstream medicine due to a lack
of experimental and clinical studies of their safety, effi-
cacy, and underlying pharmacological mechanisms.
Therefore, multi-herbal cocktails must be pre-clinically
evaluated to accurately compare traditional herbal med-
icines with modern therapeutics [4].
The traditional Oriental medicine, So-Cheong-Ryong-
Tang (CY), which is also known as Xiao-Qing-Long
Tang in China and Sho-Seiryu-To in Japan, is an herbal
mixture that has for hundreds of years been used to
treat diseases such as allergic rhinitis and asthma in
Asian countries [5, 6]. Recent evidence indicates that
the specific bioactivities of CY include the modulation
of gastrointestinal motility [7], the influencing of gene
expression in a rodent model of chronic obstructive
pulmonary disease [8], the regulation cytokines and
chemokines on allergic airway inflammation [5], and
the induction of apoptosis in human lung cancer cells
[9]. Additionally, previous studies from our laboratory
have suggested that CY has protective effects against
hydrogen peroxide-induced hepatotoxicity [10]. CY is
an aqueous polyherbal formulation that contains eight
herbs: Ephedra sinica, Schisandra chinensis, Paeonia ja-
ponica, Pinellia ternata, Cinnamomum cassia, Zingiber
officinale, Asarum sieboldii, and Glycyrrhiza glabra.
These constituent herbs and their components have
been reported to have anti-carcinogenic effects. In par-
ticular, E. sinica [11], S. chinensis [12], C. cassia [13],
and G. glabra [14] inhibit tumor growth and metastasis,
whereas P. ternate [15] and Z. officinale [16] induce
apoptosis in cancer cells. These findings suggest that
CY may have an inhibitory effect on cancer cell prolif-
eration and tumor formation. On the basis of these re-
ports, in present study, CY was treated to several
human cancer cells including AGS (gastric), HeLa (cer-
vical), and PC3 (prostate) cells. Among them, the inhib-
ition of CY against cancer cell viability showed the
strong sensitivity in AGS cells.
Tumorigenesis is caused by uncontrolled cell growth
resulting from DNA damage, the mutation of functional
genes, a dysregulation of the cell cycle, or the loss of
apoptotic functions [17]. Therefore, regulating the in-
duction of apoptosis via the modulation of signaling
pathway-related cell growth and survival is a common
and major target for cancer therapies [18]. Mitogen-
activated protein kinase (MAPK) signals such as extra-
cellular signal-regulated kinases (ERK), p38 kinases, and
c-Jun N-terminal kinases (JNK) play important roles in
cell death and survival. ERK activation may be induced
by conditions of stress caused by some agents or oxidant
injury and plays a major role in the regulation of cell
growth and differentiation. JNK and p38 are activated in
response to several stress signals, including tumor ne-
crosis factor and hyperosmotic conditions, and are asso-
ciated with induction of apoptosis [19, 20].
Recently, many researchers have adopted the use of
bioconversion techniques, such as microbial transform-
ation or bacterial fermentation, to develop natural mate-
rials with strengthened efficacy and/or targeted function.
For these purposes, research on the beneficial effects of
bioconversion using microbes has aimed to elucidate the
mechanisms of action underlying the benefits of these
natural materials and to analyze the herbal constituents
that exhibit the greatest efficacy [21–23]. In this respect,
our laboratory has previously prepared fermented CY
(FCY), analyzed its constituent compounds, and re-
ported its acute toxicity and safety using imprinting con-
trol region (ICR) mice [24]. An experimental study from
Japan investigated whether the efficacy of CY was
affected by a probiotic product, and concluded that
CY-induced anti-allergic effects were enhanced by the
probiotic [25]. In the present study, the anti-carcinogenic
effects of FCY were investigated in vitro using gastric can-
cer cells and in vivo using colon cancer cells in preclinical
experiments. The present findings indicate that FCY in-




Dulbecco’s modified Eagle’s medium (DMEM) and RPMI-
1640 were obtained from Lonza (Walkersville, MD, USA).
Fetal bovine serum (FBS), penicillin and streptomycin,
and peroxidase-conjugated secondary antibodies were
purchased from Hyclone (Logan, UT, USA). Propi-
dium iodide (PI) and 3-[4, 5-dimethylthiazol-2-ly]-2,
5-diphenyl-tetrazolium bromide (MTT) were purchased
from Sigma Chemical Co. (St. Louis, MO, USA). Caspase-
Glo 3/7, −8 and −9 assay kits were purchased from Pro-
mega (Madison, WI, USA). GAPDH, caspase-3, caspase-8,
caspase-9, PARP, cyclin D1, cyclin B1, cyclin E1, p21,
p27, ERK, phospho-ERK, p38, phospho-p38, JNK, and
phospho-JNK were purchased from Cell Signal Technology,
Inc. (Boston, MA, USA). For reference standards, ephedrine
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HCl, glycyrrhizin, 6-gingerol, gomisin A, gomisin N, paeo-
niflorin, and schisandrin were purchased from the Korea
Food and Drug Administration (Cheongwon, Korea). Cin-
namaldehyde, cinnamic acid, homogentisic acid and methyl
engenol were purchased from Sigma Chemical Co. (St.
Louis, MO, USA). HPLC grade solutions including water,
acetonitrile and methanol were purchased from J.T. Baker
(Austin, TX, USA) and Trifluoroacetic acid for analysis re-
agent was purchased from DAE JUNG Chemical & Mate-
rials Co. (Siheung, Korea).
Herb materials and preparation of fermented CY
CY was composed of 8 medicinal herbs; their constitution
ratio is shown in Table 1. The 8 herbs were purchased
from the Korea Medicine Herbs Association (Yeongcheon,
Korea). The herbal mixture was extracted by heating in
water of 8–10-fold the herb weight for 3 h at 115 °C on
Cosmos–600 extractor (Incheon, Korea). After boiling,
the extract was filtered out using standard testing sieves
(pore size, 150 μm) (Retsch, Haan, Germany) and pre-
pared in the form of powder by freeze-drying. The CY
was incubated with Lactobacilluses (1–5 × 108 CFU/mL)
obtained from the KFRI (Korea Food Research Institute,
Sungnam, Korea) to prepare fermented CY. Before use,
the bacterial strain was incubated in 50 mL of MRS broth
(Difco TM Lactobacilli MRS Broth, Becton Dickinson,
Franklin Lakes, NJ) at 37 °C overnight. The fermented CY
(FCY) by Lactobacillus at 37 °C for 48 h was filtered with
a 60 μm naylon filter (Millipore, Billerica, MA), lyophi-
lized, and stored −20 °C before use. The voucher specimen
of FCY (Registration no. CY442) was deposited in the
herbarium of KM-Based Herbal Drug Development
Group, Korea Institute of Oriental Medicine.
Characterization of phytochemicals
To determine phytochemical profile and quantify chem-
ical components of CY and FCY, HPLC analysis was per-
formed using the method reported previously with a
Dionex Ultimate 3000 HPLC system (Dionex, Germany)
and LUNA C18 column (250 × 4.60 mm i.d., 5 μm) [24].
The mobile phase was consisted of acetonitrile (A) and
0.1 % (v/v) trifluoroacetic acid (B). The line program was
well optimized and conducted as follow: 15 % A at 0–
5 min; 15–40 % A at 5–20 min; 40–45 % A at 20–
30 min; 45–43 % A at 30–40 min; and 43–100 % A at
40–60 min at a flow rate of 1.0 mL/min. The ultraviolet
(UV) spectrum was recorded between 190 and 400 nm.
The injection volume was set at 20 μL. Components
were identified via comparision of their retention times
to those of authentic standards under identifical analysis
conditions and UV spectra with an in-house PDA-
library. The standard stock solutions of the eleven refer-
ence standards were prepared by dissolving in methanol
to a final concentration of 140 μg/mL for ephedrine HCl,
240 μg/mL for paeoniflorin, 200 μg/mL for glycyrrhizin,
240 μg/mL for schidandrin, 210 μg/mL for gomisin A,
240 μg/mL for gomisin N, 265 μg/mL for 6-gingerol,
350 μg/mL for homogentisic acid, 260 μg/mL for me-
thyl engenol, 163.83 μg/mL for cinnamaldehyde, and
130 μg/mL for cinnamic acid, respectively. CY and FCY
powder were weighed and dissolved with deionized
water at a concentration of 20 mg/mL. Prior to analysis,
the extracted solution was filtered through 0.45 μm fil-
ter and maintained at 4 °C.
Cell culture
Various human cancer cell lines, obtained from the Korean
Cell Line Bank (KCLB, Seoul, Korea) and American Type
Culture Collection (ATCC, Rockville, MD), were cultured
in DMEM and RPMI-1640 supplemented with 10 % FBS.
All media contained 100 U/mL penicillin G and 100 μg/
mL streptomycin. Cells were incubated in a humidified 5 %
CO2 atmosphere at 37 °C.
Cell viability assay
Cells (4 × 103 or 5 × 103 per well) were inoculated in a
96-well plate and treated with CY or FCY for 24 or 48 h.
After incubation, cell viability was determined using
MTT colorimetric assay based on the reduction of tetra-
zolium salt to its insoluble formazan. For inhibitor study,
cells were pretreated inhibitors for 1 h and treated with
FCY for 48 h. After incubation, cell viability was deter-
mined using MTT assay.
Caspase activity assay
To determine caspase-3/7, −8, and −9 activities, cells
were seeded at a density of 1 × 104 cells/well in a 96-well
plate and treated with CY and FCY for 24 h. Caspase ac-
tivity was measured in triplicate by using a respective
Caspase-Glo 3/7, −8 and −9 assay kits according to the
manufacturer’s instructions. Culture medium was used
as a blank control and luminescence was measured
Table 1 Composition of the So-Cheong-Ryong-Tang (CY)
preparation
No. Scientific name Part used Amount used (g)
1 Ephedra sinica Radix 6
2 Schisandra chinensis Fructus 6
3 Paeonia lactiflora Radix 6
4 Pinellia ternate Rhizoma 6
5 Cinnamomum cassia Radix 4
6 Zingiber officinale Rosc. Radix 4
7 Asiasarum heterotropoides Rhizoma 4
8 Glycyrrhiza glabra Fisch. Radix 4
Total amount 40
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using an MLX microtiter luminometer (Dynex Tech-
nologies Inc., Chantilly, VA).
Cell cycle analysis
Cells were seeded at a density of 1 × 105 /mL and treated
with 500 and 1000 μg/mL FCY for 24 h. The PI staining
for cell cycle analysis was performed as described previ-
ously (Yim et al., 2011). DNA contents of the stained
cells were analyzed by FACSCalibur flow cytometry
using CellQuest software (Becton–Dickinson, Franklin
Lakes, NJ).
Detection of YO-PRO-1 uptake
For the measurement of apoptosis, cells treated with 500
and 1000 μg/mL FCY for 24 h were incubated with
apoptosis-specific dye YO-PRO-1 (1 μM, Molecular Probes,
Eugene, OR) at 4 °C for 30 min in the dark. YO-PRO-1 up-
take was directly determined with FACS Calibur flow cy-
tometry without washing or fixation and analyzed using
FCS express software.
Western blot analysis
The cell lysates treated with CY or FCY for western blot
anlaysis were prepared as described previously [26]. The
same amount of protein for each sample was electropho-
resed and transferred onto a polyvinylidene difluoride
(PVDF) membrane (Millipore, Billerica, MA). Proteins
were detected using primary antibodies specific for
GAPDH, caspase-3, caspase-8, caspase-9, PARP, cyclin
D1, cyclin B1, cyclin E1, p21, p27, ERK, phospho-ERK,
p38, phospho-p38, JNK, and phospho-JNK. This was
followed by incubation with HRP-conjugated secondary
antibodies for 1 h at room temperature. The specific
protein was detected using the enhanced chemilumines-
cence imaging system (CoreBio, Seoul, Korea).
Animals and tumor xenografts
Female mice (Athymic nu/nu, 8 weeks, 25–29 g; NARA
Bio, Seoul, Korea) were acclimated under conditions of
constant temperature (24 ± 1 °C) and humidity (55 ±
15 %) with 12-h light/dark cycle for 1 week. Mice were
injected subcutaneously with 4 × 106 HCT116 cells/
100 μL harvested and suspended in DMEM medium
without FBS. On day 5 postinoculation, mice were ran-
domized into groups (n = 4 per group) and daily admin-
istrated with saline (control), CY (157.5 or 315 mg/Kg)
or FCY (157.5 mg/Kg) in a volume of 100 μL for 14 days.
Tumor size was monitored using electronic caliper on
every alternate day and tumor volume was calculated ac-
cording to the following formula: tumor volume = length ×
width ×width/2. The experiment was terminated at the end
of 15 days when the vehicle-treated animals had large tu-
mors, and tumor was removed for the measurement of
tumor weights. The animal experimental procedures were
approved by Korea Institute of Oriental Medicine Care and
Use Committee with a reference number of #13–095 and
performed in accordance with the Korea Institute of
Oriental Medicine Care Committee Guide lines.
Statistical analysis
Data are presented as means ± SD. Student’s t-test was
employed to assess the statistical significance of differ-
ences between the control and CY- or FCY-treated groups.
Values of p <0.05 and <0.01 were considered to indicate
statistical significance.
Results
Phytochemical characterization of CY and FCY
The present study utilized high-performance liquid chro-
matography (HPLC) to analyze the 11 primary compo-
nents present in CY and FCY using conditions reported
previously [24]. Based on the stability and higher max-
imum absorption rates of the major components at base-
line, the components were selected using four ultraviolet
(UV) wavelengths: 197 nm for homogentisic acid, ephe-
drine HCl, paeoniflorin, 6-gingerol, and methyl eugenol,
215 nm for schisandrin, gomisin A, and gomisin N,
250 nm for glycyrrhizin, and 280 nm for cinnamic acid
and cinnamic aldehyde (Fig. 1a). The contents of the 11
components in CY and FCY were quantified using UV
and mass spectroscopy (MS) spectra and their retention
times were compared to standards using methods de-
scribed previously (Table 2). The quantitative analysis data
are shown in Fig. 1b. The contents of ephedrine HCl
(+102.48), glycyrrhizin (+16.98), 6-gingerol (28.03), schi-
sandrin (+13.98), and gomisin A (+69.23) in FCY were
higher than those in CY (100). In particular, the levels of
ephedrine HCl and gomisin A were markedly higher in
FCY compared to CY. In contrast, the contents of paeoni-
florin (−72.53), cinnamic acid (−15.22), and methyl eu-
genol (−44.90) in FCY were lower than those in CY (100).
The HPLC analysis detected low levels of homogentisic
acid, cinnamic aldehyde, and gomisin N; however, their
amounts were below the limits of quantification (LOQ)
and were recorded as not detected (nd).
Inhibition of cell growth by CY and FCY in human gastric
cancer cells
To further characterize the inhibitory actions of CY
and FCY on cancer cells, the abilities of these com-
pounds to suppress the growth of two gastric cancer
cell lines (AGS and NUGC-3) were evaluated. Treat-
ment with CY (500 and 1000 μg/mL) for 48 h reduced
the viability of AGS cells by 27 and 55 %, respectively,
and treatment with FCY (500 and 1000 μg/mL) inhib-
ited AGS cell growth by approximately 35 and 65 %,
respectively (Fig. 2). Additionally, the growth inhibi-
tory effect of FCY on AGS cells was significantly
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Fig. 1 HPLC-DAD analysis of CY and FCY. a Determination of eleven standard components in CY and FCY. (a) Mixed standards, (b) CY, and (c) FCY.
b Identification of changed components by bacterial fermentation in FCY compared to CY
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greater than that of CY. Similarly, treatment with either
CY or FCY (500 μg/mL) reduced the viability of NUGC-3
cells; however, this difference was not significant although
CY and FCY (1000 μg/mL) inhibited NUGC-3 cell growth.
These findings indicate that CY and its fermented formu-
lation, FCY, exert cancer-specific cytotoxic effects on AGS
cells and that FCY has greater anti-carcinogenic efficacy
than CY. Thus, the present study focused on AGS cells
for subsequent tests involving FCY.
Induction of apoptosis by FCY via the activation of
caspases in AGS cells
To determine whether the cell death induced by FCY
was related to apoptosis, the expressions of pro- and
anti-apoptosis proteins in the AGS cells were assessed
using Western blot analyses. The expression levels of
apoptosis-related proteins were clearly influenced by FCY
treatment (Fig. 3a). Compared to untreated cells, treat-
ment with FCY (500 and 1000 μg/mL) for 48 h induced
the activations of caspase-3, −8, and, −9 in AGS cells by
more than threefold. FCY treatment (1000 μg/mL; 48 h)
also increased the levels of truncated bh3-interacting do-
main death agonist (t-Bid) and cleaved poly (ADP-ribose)
polymerase (PARP) by approximately two- and four-fold.
To confirm that FCY-induced apoptosis in AGS cells
required caspase activation, a caspase activity assay was per-
formed (Fig. 3b). FCY (500 and 1000 μg/mL) increased cas-
pase activity after 48 h of treatment, and caspase-3/7, −8, and
−9 activities increased by approximately 46, 39 and 45 %, re-
spectively, after treatment with 1000 μg/mL FCY compared
to untreated cells. These data support the hypothesis that the
anti-carcinogenic effects of FCY in AGS cells were related to
apoptotic cell death resulting from the activation of caspases.
Effect of FCY on cell cycle progression in AGS cells
After treatment with FCY (500 and 1000 μg/mL) for
48 h, the AGS cells were stained with propidium iodide
(PI) and their cell cycle progression was assessed using
flow cytometry. FCY increased the number of cells in
the sub-G1 peak in a dose-dependent manner, which is
consistent with the induction of cell death (Fig. 4a).
After 48 h of treatment with FCY (500 and 1000 μg/
mL), 6.25 and 43.04 % of the cells (three- and four-fold
increases), respectively, had accumulated in the sub-G1
phase compared to untreated cells (1.92 %). Additionally,
52.11 and 26.04 % of cells treated with FCY (500 and
1000 μg/mL, respectively) had accumulated in the G1
phase after 48 h. Following treatment with FCY (500
and 1000 μg/mL), 25.31 and 19.3 % of cells accumulated
in the G2/M phase, respectively, lower than the propor-
tion of untreated cells (29.45 %).
Table 2 Characterization of the standard compounds in CY and FCY using HPLC
Compound name Classificationa tR (min) Wavelength
(nm)Standard CY FCY
1 Homogentisic acid 4 4.75 n.d. n.d. 197
2 Ephedrine HCl 1 7.11 7.08 7.30 197
3 Paeoniflorin 3 11.85 11.83 11.83 197
4 Cinnamic acid 5 21.42 21.53 22.69 280
5 Cinnamic aldehyde 5 24.58 24.59 25.27 280
6 Glycyrrhizin 8 26.35 26.45 26.93 250
7 6-Gingerol 6 33.71 33.61 33.61 197
8 Schisandrin 2 34.83 34.71 34.71 215
9 Methyl eugenol 7 37.80 37.70 37.80 197
10 Gomisin A 2 42.32 42.40 42.40 215
11 Gomisin N 2 59.29 n.d. n.d. 215
a1, Ephedra sinica; 2, Schisandra chinensis; 3, Paeonia lactiflora; 4, Pinellia ternate; 5, Cinnamomum cassia; 6, Zingiber officinale Rosc.; 7, Asiasarum heterotropoides; 8,
Glycyrrhiza glabra Fisch
Fig. 2 Inhibition of human gastric cancer cell viability by CY or FCY. AGS
and NUGC cells were treated with 500 and 1000 μg/mL for 48 h. Cell
viability was determined by MTT assay and the results are expressed as
the percentages of viable cells compared to untreated cells. The data are
shown as the means ± SD of three independent experiments
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Based on these data, the present study then investigated
whether the expressions of cell cycle-regulating proteins were
affected by FCY treatment. FCY altered the expressions of
proteins associatedwith theG1 andG2/Mphase progressions
(Fig. 4b). Specifically, the expressions of p21 and p27 increased
in conjunction with a reduction in cyclin D1 levels in a time-
dependent manner. The levels of cyclin B1, which regulates
the G2/M phase, were also decreased following treatment
with FCY, but cyclin E1 levels were unaffected.
Additionally, apoptotic cell death following FCY treatment
was assessed using YO-PRO-1 staining and flow cytometry
(Fig. 4c). Compared to untreated cells, the percentage of cells
Fig. 3 Induction of apoptosis by FCY in AGS cells. a Effects of FCY on the expressions of caspase-3, −8, and −9, and PARP cleavage. The cells
were exposed to 500 and 1000 μg/mL FCY for 24 and 48 h and protein levels were determined by Western blot analyses. The band intensity
was calculated and compared to untreated cells using ImageJ after normalization relative to GAPDH expression. b The relative luminescence
indicated the dose-dependent activations of caspase-3/7, −8, and −9 that were induced by 48 h of treatment with the indicated dose of FCY.
The data are shown as the means ± SD of three independent experiments. *P < 0.05 and **P < 0.01 versus untreated control cells
Fig. 4 Effects of FCY on cell cycle progression in AGS cells. a The cells were treated with 500 or 1000 μg/mL of FCY for 48 h, fixed with pre-chilled
70 % ethanol, stained with propidium iodide solution and then subjected to flow cytometry for determination of cell cycle distribution. b The levels of
cell cycle regulatory proteins in cells treated with FCY for 24 h were examined by Western blot analyses. c After incubation with 500 or 1000 μg/mL
FCY, apoptosis was assessed using YO-PRO-1 staining by flow cytometry. The percentage of the M2 population depicts apoptosis, which increased in
conjunction with the dose. The data are representative of three independent experiments
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distributed in the M2 population, which signifies apoptosis,
increased by approximately 5 and 11%, respectively, following
treatment with 500 and 1000 μg/mL FCY. These data indicate
that the effect of FCY on the cell cycle suppresses DNA syn-
thesis and growth in AGS cells, which are related to apoptosis.
Identification of MAPK phosphorylation by FCY for
anti-cancer activity in AGS cells
To investigate the relationship between the regulation of
MAPK pathways and the inhibition of cancer cell prolifera-
tion following FCY treatment, the FCY-induced phosphor-
ylation of MAPK proteins was analyzed by Western
blotting. The phosphorylation of MAPK cascades, including
ERK, p38, and JNK, increased after 30 min of treatment
with FCY (500 μg/mL), which was sustained for 6 h in AGS
cells (Fig. 5a). In contrast, AKT phosphorylation was transi-
ently upregulated following 6 h of exposure to FCY. To fur-
ther investigate the regulation of these signaling pathways
by FCY, AGS cells were pretreated with the MAPK inhibi-
tors PD98059 (inhibits ERK1/2), SB203580 (inhibits p38),
and SP600125 (inhibits JNK) and then treated with FCY
(500 or 1000 μg/mL) for 48 h (Fig. 5b). Each of the MAPK
inhibitors significantly diminished the anti-proliferative ef-
fects of FCY in AGS cells, especially SP203580, which re-
duced cell death by 40 % compared to 1000 μg/mL FCY.
In contrast, the anti-proliferative effects of FCY were not
enhanced by LY294002. Taken together, these data suggest
that FCY exerts anti-proliferative effects in AGS cells via
the modulation of MAPK signaling pathways, which, in
turn, results in the induction of apoptosis.
Inhibition of tumorigenic growth of cancer cells by FCY
administration in xenograft model
To confirm these observations, the inhibitory effects of
CY and FCY on tumor growth were assessed in athymic
nude mice injected with HCT116 human colon cancer
cells. Mice harboring xenograft tumors were treated or-
ally with either vehicle (control), CY-1 (157.5 mg/kg/
day), CY-2 (315 mg/kg/day), or FCY-1 (157.5 mg/kg/
day). The CY and FCY doses were based on the amounts
used in human adults (9.456 g/60 kg/day) and the yield
of the powdered extraction (23.64 %). After 6 days of
herb administration, there was an arrest in the growth of
the xenografts treated with CY-2 and FCY as well as re-
ductions in tumor size at the end of the experiment on
day 15 (Fig. 6a). Additionally, none of the orally adminis-
tered herbal formulations resulted in adverse side effects,
such as a loss of body weight or skin ulcers (Fig. 6b).
Treatment with FCY led to a significant inhibition of
48.6 % in tumor growth compared to vehicle. Although
the administration of CY-1 and CY-2 to mice harboring
xenograft tumors reduced tumor growth by approxi-
mately 16 and 30 %, respectively, these changes were not
statistically significant (Fig. 6c and d). These results pro-
vide strong evidence for the anti-carcinogenic effects of
FCY in vivo.
Discussion
Traditional medicine in Asian countries commonly in-
volves the combination of herbs to create multi-herbal
formulas for the treatment of various diseases. The use
Fig. 5 Identification of the relationship between MAPK activation and the anti-proliferative effects of FCY on AGS cells. a Cells were prepared after
treatment with 500 μg/mL FCY for 0.5, 1, 3, and 6 h, and then subjected to Western blot analyses to determine the levels of MAPK proteins, including
ERK, p38, and JNK (or AKT) and their phosphorylated forms. b Investigation of the anti-proliferative effects of FCY for 48 h using the MAPK cascade
inhibitors PD98059 (10 μM), SB203580 (5 μM), and SP600125 (10 μM), and the PI3K inhibitor LY294005 (10 μM). Cell viability was determined by MTT
assay. The results show the means ± SD of three independent experiments. *P < 0.05 and **P < 0.01 versus untreated control cells and ##P < 0.01 versus
cells treated with FCY only
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of such formulas has been scientifically verified as a com-
plementary or alternative therapy for the treatment of
cancer [27, 28]. CY is an important oriental medicine that
has traditionally been used to modulate autoimmune dis-
eases such as allergic rhinitis and asthma [5, 6, 29]. In the
present study, CY and FCY inhibited the growth of human
gastric cancer cells and cancer cell death was particularly
enhanced following treatment with FCY.
Based on these preliminary observations, the molecu-
lar mechanisms underlying the anti-carcinogenic effects
of FCY were assessed in AGS cells. Using Western blot
analyses, FCY was shown to influence the expression
levels of pro- and anti-apoptotic proteins; these results
were confirmed by caspase activity assays. The caspase
cascades are divided into two major pathways: an extrin-
sic pathway containing caspase-8 and −10 that is initi-
ated by the ligand-mediated activation of cell surface
death receptors, and an intrinsic pathway containing
caspase-9 that is activated by intracellular signals from
the mitochondria. The activation of initiator caspases
such as caspase-8, −9, and −10 by pro-apoptotic signals
leads to the downstream activation of effector caspases
such as caspase-3, −6, and −7 [30, 31]. In the present
study, the FCY-stimulated activation of caspase-8 re-
sulted in an increased level of t-Bid, which is typical of
the initiation of the extrinsic apoptosis pathway. In
turn, t-Bid influenced the activations of caspase-9 and
−3 and the cleavage of PARP. Therefore, the present
data suggest that FCY induced apoptosis via caspase-
dependent pathway in AGS cells.
The anti-proliferative effects of FCY were also identi-
fied by assessing changes in cell cycle progression. Cell
cycle checkpoints are important control mechanisms
that ensure the proper execution of cell cycle events. In
eukaryotes, the cell cycle progression is divided into
three phases: the G1/S phase, which involves DNA syn-
thesis and replication, the G2/M phase, which is associ-
ated with mitosis and complete cell division, and the
sub-G1 phase, in which the cells have left the cycle and
stopped dividing [32–34]. During FCY-induced apoptosis
in AGS cells, the expressions of G1/S and G2/M check-
point proteins, including cyclin D1, p21, p27, and cyclin
B1, were affected by FCY treatment. Additionally, the
cell population in the sub-G1 phase increased in a
concentration-dependent manner following treatment
with FCY. Thus, the present data suggest that FCY
inhibited the proliferation of cancer cells via the disrup-
tion of cell cycle progression.
MAPKs regulate cellular processes such as the prolif-
eration, differentiation, and apoptosis of cells [35]. In
particular, the pharmacological modulation of MAPK
signals influences the apoptotic response to anti-tumor
agents [19]. Furthermore, the MAPK signaling pathways
regulate diverse cellular programs by relaying extracellu-
lar signals to intracellular responses [20]. Hwang et al.
demonstrated that MAPK proteins are involved in the
Fig. 6 Inhibitory effects of FCY on in vivo tumor growth in a xenograft model. (a) The cells were injected into athymic nude mice and, 5 days after
tumor implantation, the mice were treated daily with saline (vehicle), CY (157.5 mg/kg or 315 mg/kg), or FCY (157.5 mg/kg) for 14 days. Treatment was
terminated after 15 days. (b) Changes in body weight during the administration of CY or FCY and tumor growth inhibition by (c) CY or (d) FCY.
Comparison of anti-tumor activity between vehicle and herbal formulations (CY and FCY), according to representative tumor images and tumor
weights. Data are shown as means ± SD, *P < 0.05 versus vehicle
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CY-induced modulation of pacemaker potentials in the
interstitial cells of Cajal (ICCs) [7]. Similarly, the present
study found that FCY treatment activated the ERK, p38,
and JNK signals and that these expressions were retained
during inhibiting the proliferation of AGS cells. In other
study for anti-cancer effect of CY, Park et al. demon-
strated that CY induces the apoptosis through inhibiting
the activation of PI3K/AKT signal pathway in A549 hu-
man lung carcinoma cells [9]. However, in present study,
the phosphorylation of AKT were not inhibited by FCY
in AGS cells. Additionally, in inhibitor study, the inhib-
ition of MAPK signaling by specific protein inhibitors
(ERK inhibitor: PD98059, p38 inhibitor: SB203580, and
JNK inhibitor SP600125) protected cells from the cyto-
toxic effects of FCY whereas PI3K did not contribute to
the anti-proliferative effect of FCY, which suggests that
the activation of MAPK cascades play opposite roles in
the proliferation of AGS cells.
The present results demonstrated that the fermentation
of CY generates different chemical profiles than non-
fermented CY (Fig. 1b). Bacterial fermentation either in-
creases the levels of or generates active components that
suppress tumor formation. The components that are
structurally changed following bacterial fermentation in-
clude deglycosylates, sulfates, and flavonoids; these com-
pounds increase the absorption rate of organs such as the
liver and intestine [36], and may improve the bioactivity
and bioavailability of the active components [37, 38]. In
turn, these improvements may have beneficial effects dur-
ing cancer therapy. In the present study, the fermentation
of CY with Lactobacillus delbrueckii increased the content
of active components, including ephedrine HCl, glycyrrhi-
zin, 6-gingerol, schisandrin, and gomisin A, compared to
unfermented CY. The extract of E. sinica contains ephe-
drine HCl, one of the constituents of CY, which has been
shown to possess antiangiogenic, anti-invasive, and antitu-
mor activities in B16F10 mouse melanoma cells [11]. Add-
itionally, glycyrrhizin, which is isolated from G. glabra,
has been shown to have anti-carcinogenic effects in hu-
man stomach cancer KATO III cells and promyelocytic
leukemia HL-60 cells via the induction of caspase-
dependent apoptosis [39]. Schisandrin, which is present in
the fruit of S. chinensis, inhibits the growth of by arresting
the cell cycle in the G1/G1 phase [40]. Gomisin A, which
is isolated from S. chinensis, also exerts significant anti-
carcinogenic effects. For example, gomisin A inhibits cell
proliferation and arrests the cell cycle during the G1 phase
in HeLa cells and induces apoptotic activity in HCT116
human colon cancer cells via the cleavage of caspase-7
[34, 41]. 6-Gingerol, which is the major active component
of Z. officinale, induces caspase-3-dependent apoptosis
and autophagy in HeLa cells, inhibits the growth of Lovo
human colon cancer cells by arresting the cell cycle in the
G2/M phase, and effectively suppresses tumor growth in a
HCT116 cell xenograft assay via the inhibition of leukotri-
ene A(4) hydrolase (LTA[4]H) [42–44].
Based on the above evidence, the changes in the vari-
ous components of CY following bacterial fermentation
may improve its anti-carcinogenic effects in the FCY for-
mulation. In the present xenograft assays, FCY signifi-
cantly suppressed the tumor growth of subcutaneously
injected cancer cells compared to CY. Despite the en-
hancement of anti-carcinogenic effects following fer-
mentation, there were no adverse side effects such as
body weight loss, organ abnormalities, or changes in
hematological and/or serological parameters (data not
shown). Taken together, the present results demonstrate
that the anti-carcinogenic effects of FCY may be en-
hanced compared to those of CY due to the alteration of
its active components by bacterial fermentation.
Conclusions
The present study assessed the anti-carcinogenic effects
of FCY in vitro and in vivo. The findings strongly indi-
cate that FCY induced apoptosis via the activation of
caspases and the regulation of MAPK activity in AGS
cells. Furthermore, the oral administration of FCY en-
hanced the inhibition of tumor formation, which sug-
gests that bacterial fermentation improved the inhibitory
effects of CY on cancer cells by changing the nature of
its active components. Thus, it is suggested here that
FCY may be useful as an herbal medicine for controlling
malignant tumor growth. However, additional studies
are required to identify the active components of FCY
and their capabilities.
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